Transplant News and Research

RSS

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Study reveals that kidney transplants do not affect pregnancy

Women who have had a kidney transplant and have good kidney function can get pregnant and give birth without jeopardizing their health or the health of their transplant. Having children does not affect patients' kidney function or their life-span compared with transplanted women who do not have children, according to a matching cohort study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

25 Sep 2009

Update on Cerezyme and Fabrazyme supply from Genzyme Corporation

Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

New palate reconstruction technique for post tonsil cancer surgery

A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.

23 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

SynCardia Systems and AorTech International sign technology license agreement

On Sept. 22, SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced an exclusive technology licensing agreement with AorTech International plc (AIM: AOR).

23 Sep 2009

Advanced Hair Studio to introduce genetic baldness tests in Australia

Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com)

23 Sep 2009

Leading oncology experts to discuss management of hematological malignancies

Oncology experts from leading cancer organizations from around the country, including the John Theurer Cancer Center, MD Anderson Cancer Center, the Mayo Clinic, Dana Farber Cancer Institute and the National Cancer Institute, will discuss trends in patient care, novel therapies through clinical trials and emerging concepts in the management of hematological malignancies.

23 Sep 2009

Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China

BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China, and marketing stem cell research products in China and other countries in Asia.

23 Sep 2009

Private cord blood banking can treat medical conditions but is expensive

Private cord blood banking is not cost-effective because it costs an additional $1,374,246 per life-year gained, according to a new analysis by UCSF researchers. The research team also concluded that private cord blood banking is cost-effective only for families with a child with a very high likelihood of needing a stem cell transplant.

23 Sep 2009

Carolinas HealthCare System implements Radware's application delivery solutions to prevent network downtime

Radware (Nasdaq: RDWR), the leading provider of integrated application delivery solutions for business-smart networking, today announced that Carolinas HealthCare System (CHS), the largest healthcare system in North and South Carolina, has leveraged Radware's suite of application delivery solutions in an effort to maintain a secure network environment with advanced load balancing capabilities for its extensive hospital system.

22 Sep 2009

Nasdaq issues noncompliance letter ThermoGenesis

ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Dialysis patient embarks on "Grandpa's Road Trip" with NxStage System One hemodialysis machine

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that home dialysis patient Harvey Wells, 57, has embarked on his third annual "Grandpa's Road Trip" with the NxStage(R) System One(TM). As a portable home hemodialysis machine, the NxStage System One provides Mr. Wells the opportunity to fit hemodialysis therapy into his own lifestyle and schedule. Mr. Wells is once again celebrating this freedom by traveling the country in his RV and sharing with other patients his experience doing home daily hemodialysis with the NxStage System One.

21 Sep 2009

Program to promote patients’ overall health following kidney transplant surgery

Patient adherence after a kidney transplant, or faithfully following a prescribed medical regimen, is vital to a transplant recipient's health and the survival of their new organ.

19 Sep 2009

80-unit patient housing facility for cancer patients and families

The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.

18 Sep 2009

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

Liver transplantation performed in a six-month old infant

Ila and her worried parents were referred to Lucile Packard Children's Hospital at Stanford, home of the busiest pediatric liver transplant team in the nation. The hospital's team performed more liver transplants in 2008 – the most recent reporting period – than any other U.S. children's hospital, according to the United Network for Organ Sharing. They also did the largest number of surgeries in infants like Ila, who were younger than one year when they received a transplant.

17 Sep 2009

Successful eye surgery involves eyetooth implant in eye

Blind for nine years, Sharron “Kay” Thornton has just regained her sight through a first-in-the-U.S. surgical procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The procedure -- modified osteo-odonto-keratoprosthesis (MOOKP) -- implanted her eyetooth in her eye, as a base to hold a prosthetic lens.

17 Sep 2009